By 
Motley Fool
Is Ocugen a Buy?
Despite several face-melting crashes, Ocugen’s (NASDAQ: OCGN) stock rose more than 666% this year so far, and it might have further to go, provided that its flagship coronavirus vaccine gets cleared for sales in North America. What will regulators do? The biggest questions facing Ocugen at the moment are which regulators will greenlight its vaccine, and whether any of those potential green lights might actually translate into significant revenue.
Comments